Search

Your search keyword '"Hutchings, Martin"' showing total 626 results
Start Over Author "Hutchings, Martin" Publication Year Range Last 10 years
626 results on '"Hutchings, Martin"'

1. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., Rossetti, Sára, Kicinski, Michal, van der Kaaij, Marleen A. E., Giusti, Francesco, Meijnders, Paul, Aleman, Berthe M. P., Raemaekers, John M. M., Kluin-Nelemans, Hanneke C., Spina, Michele, Fermé, Christophe, Renaud, Loïc, Casasnovas, Olivier, Stamatoullas, Aspasia, André, Marc, Le Bras, Fabien, Plattel, Wouter J., Henry-Amar, Michel, Hutchings, Martin, and Maraldo, Maja V.

Published
2024
Full Text
View/download PDF

2. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Author

Linton, Kim M, Vitolo, Umberto, Jurczak, Wojciech, Lugtenburg, Pieternella J, Gyan, Emmanuel, Sureda, Anna, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David John, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Sancho, Juan-Manuel, Cochrane, Tara, Leppä, Sirpa, Chamuleau, Martine E D, Gernhardt, Diana, Altıntaş, Işıl, Liu, Yan, Ahmadi, Tahamtan, Dinh, Minh H, Hoehn, Daniela, Favaro, Elena, Elliott, Brian, Thieblemont, Catherine, and Vose, Julie M

Published
2024
Full Text
View/download PDF

3. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Author

Dreyling, Martin, Doorduijn, Jeanette, Giné, Eva, Jerkeman, Mats, Walewski, Jan, Hutchings, Martin, Mey, Ulrich, Riise, Jon, Trneny, Marek, Vergote, Vibeke, Shpilberg, Ofer, Gomes da Silva, Maria, Leppä, Sirpa, Jiang, Linmiao, Stilgenbauer, Stephan, Kerkhoff, Andrea, Jachimowicz, Ron D, Celli, Melania, Hess, Georg, Arcaini, Luca, Visco, Carlo, van Meerten, Tom, Wirths, Stefan, Zinzani, Pier Luigi, Novak, Urban, Herhaus, Peter, Benedetti, Fabio, Sonnevi, Kristina, Hanoun, Christine, Hänel, Matthias, Dierlamm, Judith, Pott, Christiane, Klapper, Wolfram, Gözel, Döndü, Schmidt, Christian, Unterhalt, Michael, Ladetto, Marco, and Hoster, Eva

Published
2024
Full Text
View/download PDF

7. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Author

Driessen, Julia, Kersten, Marie José, Visser, Lydia, van den Berg, Anke, Tonino, Sanne H., Zijlstra, Josée M., Lugtenburg, Pieternella J., Morschhauser, Franck, Hutchings, Martin, Amorim, Sandy, Gastinne, Thomas, Nijland, Marcel, Zwezerijnen, Gerben J. C., Boellaard, Ronald, de Vet, Henrica C. W., Arens, Anne I. J., Valkema, Roelf, Liu, Roberto D. K., Drees, Esther E. E., de Jong, Daphne, Plattel, Wouter J., and Diepstra, Arjan

Published
2022
Full Text
View/download PDF

9. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours

Author

Nanni, Cristina, Kobe, Carsten, Baeßler, Bettina, Baues, Christian, Boellaard, Ronald, Borchmann, Peter, Buck, Andreas, Buvat, Irène, Chapuy, Björn, Cheson, Bruce D, Chrzan, Robert, Cottereau, Ann-Segolene, Dührsen, Ulrich, Eikenes, Live, Hutchings, Martin, Jurczak, Wojciech, Kraeber-Bodéré, Françoise, Lopci, Egesta, Luminari, Stefano, MacLennan, Steven, Mikhaeel, N George, Nijland, Marcel, Rodríguez-Otero, Paula, Treglia, Giorgio, Withofs, Nadia, Zamagni, Elena, Zinzani, Pier Luigi, Zijlstra, Josée M, Herrmann, Ken, and Kunikowska, Jolanta

Published
2023
Full Text
View/download PDF

11. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Author

Karimi, Yasmin, primary, Thieblemont, Catherine, additional, Ghesquieres, Hervé, additional, Cheah, Chan Y, additional, Clausen, Michael Roost, additional, Cunningham, David, additional, Jurczak, Wojciech, additional, Linton, Kim M., additional, Hutchings, Martin, additional, Phillips, Tycel Jovelle, additional, Farooq, Umar, additional, Kim, Won Seog, additional, Dinh, Minh H, additional, Ghosh, Jagannath, additional, Pallai, Rajash, additional, Wielgos-Bonvallet, Monica, additional, Eskelund, Christian, additional, Lugtenburg, Pieternella, additional, and Vose, Julie, additional

Published
2024
Full Text
View/download PDF

12. Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.

Author

Bartlett, Nancy L., primary, Dickinson, Michael, additional, Hutchings, Martin, additional, Carlo-Stella, Carmelo, additional, Wu, Shang-Ju, additional, Leppä, Sirpa, additional, Trneny, Marek, additional, Corradini, Paolo, additional, Offner, Fritz, additional, Mulvihill, Estefania, additional, Bottos, Alessia, additional, Chohan, Saibah, additional, Baumlin, Pauline, additional, Relf, James, additional, Lundberg, Linda, additional, and Bachy, Emmanuel, additional

Published
2024
Full Text
View/download PDF

14. Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.

Author

Vandtved, Julie Haugaard, Øvlisen, Andreas Kiesbye, Baech, Joachim, Weinrich, Ulla Møller, Severinsen, Marianne Tang, Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Glimelius, Ingrid, Kamper, Peter, Hutchings, Martin, Specht, Lena, Dahl‐Sørensen, Rasmus, Christensen, Jacob Haaber, and El‐Galaly, Tarec C.

Subjects
OBSTRUCTIVE lung diseases, INTERSTITIAL lung diseases, PULMONARY fibrosis, CHRONIC obstructive pulmonary disease, LUNG diseases
Abstract

Summary: Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin‐containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population‐based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age‐ and sex‐matched comparators from the background population. Median follow‐up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30–3.68]), with a 10‐year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35–26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43–2.76]), with a 10‐year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43–1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B‐symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work‐up of pulmonary symptoms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Reply to T. Vassilakopoulos et al

Author

Federico, Massimo, primary, Plattel, Wouter, additional, Hutchings, Martin, additional, Stepanishyna, Yana, additional, Fortpied, Catherine, additional, and André, Marc, additional

Published
2024
Full Text
View/download PDF

16. Machine Learning–Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma

Author

Rask Kragh Jørgensen, Rasmus, primary, Bergström, Fanny, additional, Eloranta, Sandra, additional, Tang Severinsen, Marianne, additional, Bjøro Smeland, Knut, additional, Fosså, Alexander, additional, Haaber Christensen, Jacob, additional, Hutchings, Martin, additional, Bo Dahl-Sørensen, Rasmus, additional, Kamper, Peter, additional, Glimelius, Ingrid, additional, E Smedby, Karin, additional, K Parsons, Susan, additional, Mae Rodday, Angie, additional, J Maurer, Matthew, additional, M Evens, Andrew, additional, C El-Galaly, Tarec, additional, and Hjort Jakobsen, Lasse, additional

Published
2024
Full Text
View/download PDF

17. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Author

Dickinson, Michael, Briones, Javier, Herrera, Alex F., González-Barca, Eva, Ghosh, Nilanjan, Cordoba, Raul, Rutherford, Sarah C., Bournazou, Eirini, Labriola-Tompkins, Emily, Franjkovic, Izolda, Chesne, Evelyne, Brouwer-Visser, Jurriaan, Lechner, Katharina, Brennan, Barbara, Nüesch, Eveline, DeMario, Mark, Rüttinger, Dominik, Kornacker, Martin, and Hutchings, Martin

Published
2021
Full Text
View/download PDF

19. Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim M, primary, Jurczak, Wojciech, additional, Lugtenburg, Pieternella J., additional, Gyan, Emmanuel, additional, Sureda, Anna, additional, Christensen, Jacob Haaber, additional, Hess, Brian, additional, Tilly, Herve, additional, Cordoba, Raul, additional, Lewis, David John, additional, Okada, Craig, additional, Hutchings, Martin, additional, Clausen, Michael Roost, additional, Vitolo, Umberto, additional, Cochrane, Tara, additional, Leppä, Sirpa, additional, Chamuleau, Martine E.D., additional, Conlon, Rebekah, additional, Favaro, Elena, additional, Favaro, Diana, additional, Altıntaş, Işıl, additional, Liu, Yan, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

21. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Author

Hutchings, Martin, Mous, Rogier, Clausen, Michael Roost, Johnson, Peter, Linton, Kim M, Chamuleau, Martine E D, Lewis, David John, Sureda Balari, Anna, Cunningham, David, Oliveri, Roberto S, Elliott, Brian, DeMarco, Dena, Azaryan, Ada, Chiu, Christopher, Li, Tommy, Chen, Kuo-mei, Ahmadi, Tahamtan, and Lugtenburg, Pieternella J

Published
2021
Full Text
View/download PDF

22. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Author

Straus, David J, Długosz-Danecka, Monika, Connors, Joseph M, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Munoz, Javier, Lee, Hun Ju, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M, Younes, Anas, Gallamini, Andrea, Liu, Rachael, Little, Meredith, Fenton, Keenan, Fanale, Michelle, and Radford, John

Published
2021
Full Text
View/download PDF

23. Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma

Author

Rask Kragh Jørgensen, Rasmus, Bergström, Fanny, Eloranta, Sandra, Tang Severinsen, Marianne, Bjøro Smeland, Knut, Fosså, Alexander, Haaber Christensen, Jacob, Hutchings, Martin, Bo Dahl-Sørensen, Rasmus, Kamper, Peter, Glimelius, Ingrid, E Smedby, Karin, K Parsons, Susan, Mae Rodday, Angie, J Maurer, Matthew, M Evens, Andrew, C El-Galaly, Tarec, Hjort Jakobsen, Lasse, Rask Kragh Jørgensen, Rasmus, Bergström, Fanny, Eloranta, Sandra, Tang Severinsen, Marianne, Bjøro Smeland, Knut, Fosså, Alexander, Haaber Christensen, Jacob, Hutchings, Martin, Bo Dahl-Sørensen, Rasmus, Kamper, Peter, Glimelius, Ingrid, E Smedby, Karin, K Parsons, Susan, Mae Rodday, Angie, J Maurer, Matthew, M Evens, Andrew, C El-Galaly, Tarec, and Hjort Jakobsen, Lasse

Abstract

Purpose Patients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS). Patients and Methods This study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort). Results In total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis. Conclusion The new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-H, PURPOSE: Patients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS). PATIENTS AND METHODS: This study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort). RESULTS: In total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis. CONCLUSION: The new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-HIPI.

Published
2024

28. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy

Author

Crombie, Jennifer L., primary, Graff, Tara, additional, Falchi, Lorenzo, additional, Karimi, Yasmin H., additional, Bannerji, Rajat, additional, Nastoupil, Loretta J, additional, Thieblemont, Catherine, additional, Ursu, Renata, additional, Bartlett, Nancy L., additional, Nachar, Victoria R, additional, Weiss, Jonathan, additional, Osterson, Jane, additional, Patel, Krish, additional, Brody, Joshua D., additional, Abramson, Jeremy S, additional, Lunning, Matthew A, additional, Shah, Nirav N., additional, Ayed, Ayed, additional, Kamdar, Manali, additional, Parsons, Benjamin M., additional, Caimi, Paolo, additional, Flynn, Ian W., additional, Herrera, Alex F., additional, Sharman, Jeff P., additional, McKenna, Marshall, additional, Armand, Philippe, additional, Kahl, Brad S., additional, Smith, Sonali M, additional, Zelenetz, Andrew D, additional, Budde, Lihua E, additional, Hutchings, Martin, additional, Phillips, Tycel J., additional, and Dickinson, Michael, additional

Published
2024
Full Text
View/download PDF

30. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma

Author

Federico, Massimo, primary, Fortpied, Catherine, additional, Stepanishyna, Yana, additional, Gotti, Manuel, additional, van der Maazen, Richard, additional, Cristinelli, Caterina, additional, Re, Alessandro, additional, Plattel, Wouter, additional, Lazarovici, Julien, additional, Merli, Francesco, additional, Specht, Lena, additional, Schiano de Colella, Jean-Marc, additional, Hutchings, Martin, additional, Versari, Annibale, additional, Edeline, Véronique, additional, Stamatoulas, Aspasia, additional, Girinsky, Theodore, additional, Ricardi, Umberto, additional, Aleman, Berthe, additional, Meulemans, Bart, additional, Tonino, Sanne, additional, Raemaekers, John, additional, and André, Marc, additional

Published
2023
Full Text
View/download PDF

32. IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

Author

Merryman, Reid W., primary, Belada, David, additional, Sureda, Anna, additional, Leppä, Sirpa, additional, Vermaat, Joost S.P., additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Christensen, Jacob Haaber, additional, Wahlin, Björn E., additional, Linton, Kim M., additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

33. Oral Abstract: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

34. POSTER: ABCL-478 Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

Author

Dickinson, Michael, primary, Carlo-Stella, Carmelo, additional, Morschhauser, Franck, additional, Bachy, Emmanuel, additional, Corradini, Paolo, additional, Iacoboni, Gloria, additional, Khan, Cyrus, additional, Wróbel, Thomasz, additional, Offner, Fritz, additional, Trněný, Marek, additional, Wu, Shang-Ju, additional, Cartron, Guillaume, additional, Hertzberg, Mark, additional, Sureda, Anna, additional, Perez-Callejo, David, additional, Lundberg, Linda, additional, Relf, James, additional, Clark, Emma, additional, Humphrey, Kathryn, additional, and Hutchings, Martin, additional

Published
2023
Full Text
View/download PDF

35. ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

36. ABCL-478 Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

Author

Dickinson, Michael, primary, Carlo-Stella, Carmelo, additional, Morschhauser, Franck, additional, Bachy, Emmanuel, additional, Corradini, Paolo, additional, Iacoboni, Gloria, additional, Khan, Cyrus, additional, Wróbel, Thomasz, additional, Offner, Fritz, additional, Trněný, Marek, additional, Wu, Shang-Ju, additional, Cartron, Guillaume, additional, Hertzberg, Mark, additional, Sureda, Anna, additional, Perez-Callejo, David, additional, Lundberg, Linda, additional, Relf, James, additional, Clark, Emma, additional, Humphrey, Kathryn, additional, and Hutchings, Martin, additional

Published
2023
Full Text
View/download PDF

37. POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

38. POSTER: IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

Author

Merryman, Reid W., primary, Belada, David, additional, Sureda, Anna, additional, Leppä, Sirpa, additional, Vermaat, Joost S.P., additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Christensen, Jacob Haaber, additional, Wahlin, Björn E., additional, Linton, Kim M., additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

40. P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Author

Jurczak, Wojciech, primary, Ghesquieres, Herve, additional, Karimi, Yasmin, additional, Cheah, Chan, additional, Roost Clausen, Michael, additional, Cunningham, David, additional, Rok Do, Young, additional, Lewis, David, additional, Gasiorowski, Robin, additional, Min Kim, Tae, additional, Poel, Marjolein Van Der, additional, Limei Poon, Michelle, additional, Feldman, Tatyana, additional, Linton, Kim, additional, Sureda, Anna, additional, Hutchings, Martin, additional, Kanoun, Salim, additional, Vercellino, Laetitia, additional, Cota Stirner, Mariana, additional, Mcgoldrick, Stephanie, additional, Liu, Yan, additional, Sacchi, Mariana, additional, Lugtenburg, Pieternella, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

41. S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

Author

Sureda, Anna, primary, Falchi, Lorenzo, additional, Leppa, Sirpa, additional, Vermaat, Joost, additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Merryman, Reid W., additional, Christensen, Jacob Haaber, additional, Wahlin, Bjorn, additional, Linton, Kim, additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Belada, David, additional

Published
2023
Full Text
View/download PDF

42. P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

Author

Hutchings, Martin, primary, Carlo-Stella, Carmelo, additional, Morschhauser, Franck, additional, Dickinson, Michael, additional, Bachy, Emmanuel, additional, Cartron, Guillaume, additional, Khan, Cyrus, additional, Tani, Monica, additional, Martinez-Lopez, Joaquín, additional, Bartlett, Nancy L., additional, Salar, Antonio, additional, Brody, Joshua, additional, Leppa, Sirpa, additional, Baumlin, Pauline, additional, Lundberg, Linda, additional, Relf, James, additional, Xie, Yuying, additional, Bottos, Alessia, additional, Humphrey, Kathryn, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

44. ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Doerr, Thomas, Kilavuz, Nurgul, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Hutchings, Martin, and Lugtenburg, Pieternella

Published
2022
Full Text
View/download PDF

45. HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

Author

Straus, David, Radford, John, Connors, Joseph, Kim, Won Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan, Advani, Ranjana, Hutchings, Martin, Evens, Andrew, Smolewski, Piotr, Savage, Kerry, Bartlett, Nancy, Eom, Hyeon-Seok, Abramson, Jeremy, Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, and Ansell, Stephen

Published
2022
Full Text
View/download PDF

46. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

Author

El-Galaly, Tarec Christoffer, Cheah, Chan Yoon, Bendtsen, Mette Dahl, Nowakowski, Grzegorz S., Kansara, Roopesh, Savage, Kerry J., Connors, Joseph M., Sehn, Laurie H., Goldschmidt, Neta, Shaulov, Adir, Farooq, Umar, Link, Brian K., Ferreri, Andrés J.M., Calimeri, Teresa, Cecchetti, Caterina, Dann, Eldad J., Thompson, Carrie A., Inbar, Tsofia, Maurer, Matthew J., Gade, Inger Lise, Juul, Maja Bech, Hansen, Jakob W., Holmberg, Staffan, Larsen, Thomas S., Cordua, Sabrina, Mikhaeel, N. George, Hutchings, Martin, Seymour, John F., Clausen, Michael Roost, Smith, Daniel, Opat, Stephen, Gilbertson, Michael, Thanarajasingam, Gita, and Villa, Diego

Published
2018
Full Text
View/download PDF

47. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Author

Cottereau, Anne-Ségolène, Versari, Annibale, Loft, Annika, Casasnovas, Olivier, Bellei, Monica, Ricci, Romain, Bardet, Stéphane, Castagnoli, Antonio, Brice, Pauline, Raemaekers, John, Deau, Bénédicte, Fortpied, Catherine, Raveloarivahy, Tiana, Van Zele, Emelie, Chartier, Loic, Vander Borght, Thierry, Federico, Massimo, Hutchings, Martin, Ricardi, Umberto, Andre, Marc, and Meignan, Michel

Published
2018
Full Text
View/download PDF

48. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma

Author

Buske, Christian, Dreyling, Martin, Ferreri, Andrés J M, Fields, Paul, Gaidano, Gianluca, Goede, Valentin, Hutchings, Martin, Ladetto, Marco, Le Gouill, Steven, Luminari, Stefano, Mey, Ulrich, de Nully Brown, Peter, Pfreundschuh, Michael, Pott, Christiane, Schmitz, Norbert, Soubeyran, Pierre, Spina, Michele, Stauder, Reinhard, Balari, Anna Sureda, Trněný, Marek, van Imhoff, Gustaaf, Walewski, Jan, Wedding, Ulrich, Zamò, Alberto, Zucca, Emanuele, Buske, C., Hutchings, M., Ladetto, M., Goede, V., Mey, U., Soubeyran, P., Spina, M., Stauder, R., Trněný, M., Wedding, U., and Fields, P.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results